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Hypertension induced hypertrophy and diastolic dysfunction and is associated with cardiac oxidation
and reduced NO production. We hypothesized that tetrahydrobiopterin (BH4) can regulate the phos-
phatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway and reverse cardiac hypertrophy
and diastolic dysfunction in spontaneously hypertensive rats. Ten-week-old male spontaneously hy-
pertensive rats (SHR) and age-matched normotensive control Wistar-Kyoto (WKY) rats were divided into
ﬁve groups, WKY, WKY þ BH4, SHR, SHR þ BH4 and SHR þ VAL. In SHR, diastolic dysfunction was
accompanied by concentric hypertrophy, cardiac oxidation, and reduced cardiac BH4 and NO production.
Four-week BH4 and valsartan administration reversed hypertrophy and improved diastolic function. BH4
and valsartan blunted the expression of hypertrophy markers a-skeletal actin (a-SA) and b-myosin heavy
chain (b-MHC). Only BH4 reduced hypertension and induced myocardial ﬁbrosis and expression of
transforming growth factor-b1 (TGF-b1). BH4 reduced cardiac oxidant stress and increased NO pro-
duction. Exogenous BH4 increased phosphorylated Akt levels and increased Bcl-2 expression.
In conclusion, less BH4 and reduced NO increases myocardial hypertrophy and cardiac oxidative stress,
which exacerbates diastolic dysfunction. Exogenous BH4 ameliorates cardiac hypertrophy and diastolic
dysfunction through the PI3K/p-Akt pathway. BH4 may be a potent therapy for hypertension with dia-
stolic dysfunction.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypertension is one of the most common diseases in primary
care and an important preventable contributor to disease and death
[1,2]. Hypertension-induced hypertrophy increases the risk for
heart failure [3], especially left ventricular (LV) diastolic dysfunc-
tion, i.e., delayed relaxation and augmented diastolic stiffness.
There are no speciﬁc treatments for diastolic dysfunction, partly
because of a relative lack of a mechanistic understanding of this
disorder [4e7]. Recently, Silberman et al. demonstrated that LV, Lanzhou University Second
, PR China.
Inc. This is an open access article udiastolic dysfunction was associated with cardiac oxidation and
reduced NO production [8].
Nitric oxide (NO), an endothelium-derived relaxing factor [9], is
an important regulator of vascular tone and blood pressure and is
synthesized by endothelial NO synthase 6 (eNOS6) [10]. Blocking
eNOS with pharmacological inhibitors causes signiﬁcant peripheral
vasoconstriction and elevated blood pressure [11]. Tetrahy-
drobiopterin (BH4) is a cofactor of nitric oxide synthase (NOS).
Nitric oxide (NO) bioavailability is reduced during the early stages
of hypertension [12e14].
The role of myocardial apoptosis has been recognized in
abnormal cardiac function [15]. Cardiac oxidation has been linked
to progression of left ventricular hypertrophy and diastolic
dysfunction [16]. The phosphatidylinositol 3-kinase (PI3K)
signaling pathway is an important regulatory pathway implicated
in the regulation of cell proliferation, angiogenesis and apoptosis
[17,18].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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up-regulates phosphorylated Akt levels and reverses cardiac hy-
pertrophy and diastolic dysfunction in spontaneously hypertensive
rats.2. Methods
2.1. Animals
Ten-week-old male spontaneously hypertensive rats (SHR) and
age-matched normotensive control Wistar-Kyoto (WKY) rats were
obtained from Vital River Laboratory Animal Technology Co., Ltd
(Beijing, China). Rats were housed in a 22 ± 2 C roomwith a 12:12-
h light/dark cycle (lights on at 07:00) and access to food and tap
water ad libitum.
All experiments were conducted in accordance with the Na-
tional Institutes of Health's Guide for the Care and Use of Labora-
tory Animals (National Academy Press, revised 1996). All
experiments were performed under sodium pentobarbital anes-
thesia, and all efforts were made to minimize suffering.2.2. Drug preparation
The rats were divided into ﬁve groups. WKY þ BH4 (n ¼ 16) and
SHR þ BH4 (n ¼ 16) groups received BH4 200 mg/kg/d (Schircks
Laboratories, Jona, Switzerland) by gavage for four weeks. WKYand
SHR control (n ¼ 16) groups received the same volume of sterile
water as vehicle. The SHR þ VAL group (n ¼ 16) were received
valsartan 30 mg/kg/day by gavage for four weeks.2.3. Blood pressure measurement
After four weeks of treatment, we measured blood pressure
using the standard tail-cuff method with a NIBP (non-invasive
blood pressure) controller system (ADInstruments Pty Ltd., Castle
Hill, NSW, Australia). A programmable sensor attached to a tail cuff
was used to monitor tail pulse waves and measure blood pressure
when the pulse waves became stable and rhythmic. Systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were averaged
from ﬁve recordings.2.4. Cardiac function and geometry assessed by echocardiography
Rats were anesthetized with sodium pentobarbital (50 mg/kg,
i.p.), maintained at 37 C, and studied by echocardiography (Vivid
E9, GE, Pittsburgh, PA, USA; Probe i13L Intraoperative Linear Probe).
M-mode images in the parasternal long-axis and LV short-axis
views at the midpapillary level were taken. Measurements were
averaged from ﬁve consecutive beats at end-expiration. Baseline
images prior to treatment were acquired in all groups. After four
weeks of treatment, the rats underwent echocardiography again.Table 1
Body weight, heart weight and blood pressure.
Parameters WKY (n ¼ 6) WKY þ BH4 (n ¼ 6)
BW (g) 305 ± 11 299 ± 15
HW (mg) 784 ± 32.2# 789 ± 27.9
HW/BW (mg/g) 2.57 ± 0.10## 2.65 ± 0.17##
SBP (mmHg) 122 ± 6.8## 120 ± 7.6##
DBP (mmHg) 76 ± 5.3## 75 ± 7.1##
HR (bpm) 388 ± 16 396 ± 16
HW/BW: heart weight to body weight, SBP: systolic blood pressure, DBP: diastolic blood
*P < 0.05 and **P < 0.01 vs. WKY, #P < 0.05 and ##P < 0.01 vs. SHR.2.5. Hemodynamic measurements
The Mikro-Tip® pressure volume (PV) catheter and MPVS Ul-
tra™ system (Millar Instruments, Houston, TX, USA) were used to
assess left ventricular function. Body temperature was maintained
at 37 C using a rectal thermometer probe and DC temperature
control module (FHC, New Brunswick, ME, USA).
2.6. Measurement of cardiac BH4 and BH2
Hearts were rapidly excised and stored in liquid nitrogen. BH4,
BH2 and biopterin were assessed with HPLC analysis (System
GOLD, Beckman Coulter) using a differential oxidation method
described previously [19,20] in homogenized heart samples. Data
were analyzed using 32 Karat chromatography software (Beckman
Coulter) and are expressed as nmol/mg tissue.
2.7. Measurement of NO generation
NO was measured in myocardium using the NO detection kit
(Biovision, Mountain View, CA, USA) according to the manufac-
turer's instructions. The optical density values of the samples were
measured at 540 nm on a spectrophotometer (Beckman DU530,
Beckman Coulter, Brea, CA, USA).
2.8. Cardiac cyclic guanosine monophosphate, malondialdehyde
and superoxide dismutase
Oxidative stress markers, including cyclic guanosine mono-
phosphate (cGMP), superoxide dismutase (SOD) and malondial-
dehyde (MDA), were measured in left ventricular myocardium
tissue using ELISA kits (Nanjing Jiancheng Bioengineering Institute,
Nanjing, China) according to the manufacturer's instructions.
2.9. Quantitative real-time polymerase chain reaction (PCR)
Heart tissues were homogenized in liquid nitrogen, and total
RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA,
USA). Quantitative RT-PCR was performed with an Applied Bio-
systems Prism 7900 Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA). All primers for RT-PCR of b-myosin
heavy chain (b-MHC), a-skeletal actin (a-SA) and transforming
growth factor-beta 1 (TG-Fb1) were designed by TaKaRa (TaKaRa,
Dalian, China). The mRNA levels of b-MHC, a-SA and TGF-b1 were
normalized to that of GAPDH.
2.10. Western blot analysis
The frozen left ventricular tissue tissues were homogenized in
RIPA buffer containing protease inhibitors. The BCA Protein Array
Kit (Pierce, Rockford, IL, USA) was used for protein quantiﬁcation.
The NC membrane was blocked with 5% skim milk in Tris-buffered
saline with primary antibody against phosphatidylinositol 3-kinaseSHR (n ¼ 6) SHR þ BH4 (n ¼ 6) SHR þ VAL (n ¼ 6)
269 ± 8* 244 ± 10* 247 ± 8*
821 ± 36.2* 755 ± 20.5## 747 ± 17.7##
3.30 ± 0.19** 3.11 ± 0.18# 3.02 ± 0.07##
209 ± 9.4** 198 ± 8.9**# 171 ± 9.0**##
113 ± 11.1** 102 ± 4.1*## 96 ± 9.2*##
398 ± 12 395 ± 20 398 ± 13
pressure, HR: heart rate. Values are presented as the mean ± S.D.
Fig. 1. Hypertrophy and diastolic dysfunction in hypertensive rats was associated with cardiac oxidation. A and B: Echocardiographic assessment by B-type echo at a mid-LV short-
axis view. C and D: Echocardiographic assessment with M-mode. E and F: Transmitral ﬂow Doppler. G and H: Mitral annulus tissue Doppler. I and J: LV inﬂow propagation velocity
(Vp) with M-mode. Twelve-week-old SHR exhibited greater hypertrophy and worsening diastolic dysfunction. KeQ: EF, ejection fraction; FS, fractional shortening; E0 , mitral annulus
longitudinal velocity tissue Doppler early ﬁlling; A0 , mitral annulus longitudinal velocity tissue Doppler late ﬁlling; IVRT, isovolumetric relaxation time; and Vp, LV inﬂow prop-
agation velocity. R, S and T: Invasive hemodynamic assessment of LV diastolic dysfunction. LVEDP: LV end-diastolic pressure; EDPVR, end-diastolic pressureevolume relationship;
and Tau (Glantz), time constants for isovolumic relaxation. n ¼ 6 per group for echocardiographic and hemodynamic assessments. UeW: Cardiac oxidative stress in SHR and WKY,
n ¼ 12 per group. cGMP: cyclic guanosine monophosphate, SOD: superoxide dismutase, MDA: malondialdehyde. Data are presented as the mean ± SD.*P < 0.05 and **P < 0.01 vs.
WKY, #P < 0.05 and ##P < 0.01 vs. SHR.
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Fig. 2. Less cardiac BH4 and reduced NO in hypertensive rats with diastolic dysfunction. AeC: Cardiac BH4 and BH2 levels and BH4/BH2 ratio. D: Cardiac NO production. Data are
presented as the mean ± SD.*P < 0.05 and **P < 0.01 vs. WKY, #P < 0.05 and ##P < 0.01 vs. SHR.
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1:1000 diluted, Cell Signaling Inc.) and phosphorylated Akt-Ser473
(60 kDa, 1:1000 diluted, Cell Signaling Inc.), Akt-Thr308 (60 kDa,
1:1000 diluted, Cell Signaling Inc.). Secondary antibody (1:2000
diluted) was incubated at room temperature for 1 h and then
washed three times for 15min. GAPDH (37 kDa,1:5000, Santa Cruz)
was used to control for protein loading. The target proteins were
detected with ECL plus detection reagents (Amersham, Pittsburgh,
PA, USA). Immunoreactive bands were visualized by enhanced
chemiluminescence (Pierce, Rockford, IL). Protein expression was
assessed by densitometric analysis using Image J software (NIH).
2.11. Immunohistochemistry
Fixed heart tissues were embedded in parafﬁn, and cardiac tis-
sue slices were obtained from the mid-LV level. The frozen samples
were cut into sections at a thickness of 6 mm. The sections were
incubated for 3 h at room temperature with the antibody against
vascular endothelial growth factor (VEGF), B cell lymphoma/
lewkmia-2 (BCL-2) and Bcl-2-associated X protein (Bax) at a dilu-
tion of 1:100 and washed with PBS. The positive immunostained
areas were quantiﬁed with an image analysis system (Olympus
Optical, Tokyo, Japan).
2.12. Statistical analysis
All data are expressed as the mean ± S.D. Multiple groups were
compared using one-way ANOVA, followed by the least signiﬁcant
difference test. A probability level of 0.05 or less was consideredstatistically signiﬁcant. The statistical analysis was performed with
the GraphPad Prism 5.0 statistical package program (GraphPad
Software, Inc., La Jolla, CA, USA).
3. Results
3.1. Body weight, heart weight and blood pressure
After four weeks of treatment, body weight was measured in all
groups. As shown in Table 1, body weight in the WKY rats was
signiﬁcantly heavier than the SHR rats, but no signiﬁcant differ-
ences were observed between the SHR groups. Heart weight in the
SHR group was signiﬁcantly higher compared with the SHR þ BH4
and SHR þ VAL groups. Compared with the SHR group, BH4 and
valsartan treatment induced a signiﬁcantly lower heart weight to
body weight ratio, but no signiﬁcant differences in the ratio were
observed between the BH4 and valsartan groups.
Both systolic and diastolic blood pressurewas signiﬁcantly higher
in the SHR groups than the age-matched WKY rats. SBP was
209 ± 9.4 mmHg after vehicle administration in the SHR group but
was signiﬁcantly decreased to 171 ± 9.0 mmHg by valsartan and
198±8.9mmHgbyBH4.DBPexhibited the samepatterns asSBP inall
groups (Table1). Heart rate did not signiﬁcantly change ineachgroup.
3.2. Hypertensive rats exhibited hypertrophy, and diastolic
dysfunction was associated with cardiac oxidation
Spontaneously hypertensive rats exhibited concentric hyper-
trophy and diastolic dysfunction with preserved systolic function,
Fig. 3. BH4 reversed hypertrophic remodeling. A and B: Echocardiographic assessment with B-type and M-mode at a mid-LV short-axis view. C and D: Protein expression with
immunohistochemical staining of Bax and Bcl-2 in myocardium (400). EeG: TaqMan real-time polymerase chain reaction analysis of mRNA expression of genetic markers of
myocardial hypertrophy, including a-SA (a-skeletal actin) and b-MHC (b-myosin heavy chain) mRNA levels. Data are presented as the mean ± SD.*P < 0.05 and **P < 0.01 vs. WKY,
#P < 0.05 and ##P < 0.01 vs. SHR.
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Supplemental Data and Fig. 1EeJ). The interventricular septal dia-
stolic thickness (IVSd) and left ventricular posterior wall diastolic
thickness (LVPWd) of SHR rats were signiﬁcantly thicker thanWKY
rats in the LV M-Mode Protocol due to chronic high blood pressure
(Fig. 1AeD). Comparing with age-matched WKY rats, the ejection
fraction (EF%), fractional shortening (FS%), LVEDD and LVESD of SHR
were not different (see Supplemental Data and Fig. 1K, L),suggesting that there was no morphologic or systolic functional
damage in early age in spontaneously hypertensive rats.
SHR exhibited signiﬁcant reductions in tissue mitral annulus
early longitudinal (E0) velocities, as well as the ratio of early annulus
to late annulus velocities (E0/A0). The ratio of early diastolic ﬁlling
velocity to early diastolic mitral annulus velocity (E/E0) has reported
to be best correlated with invasive hemodynamic measures of
diastolic dysfunction [21]. SHR had a higher E/E0 compared with
Fig. 4. BH4 restored LV diastolic function and up-regulated phosphorylated Akt levels. AeC: Cardiac diastolic function assessed by echocardiography (n ¼ 6 per group). A: Mitral
inﬂow patterns. B: Tissue Doppler mitral annular and late diastolic velocities. C: Color M-mode ﬂow propagation with velocity (Vp). DeF: Cardiac diastolic function as assessed by
hemodynamics. nD: LVEDP, LV end-diastolic pressure. E: EDPVR, end-diastolic pressureevolume relationship. F: Tau (Glantz), time constants for isovolumic relaxation. GeK:
Western blot analysis for PI3K and Akt expression and phosphorylation. G: PI3K and Akt western blots. H: Phosphorylation of Akt at Ser473 and Thr308 western blots. I: Ratio of PI3K
to GAPDH. J: Ratio of phosphorylated S473-Akt to total Akt. K Ratio of phosphorylated T308-Akt to total Akt. Data are presented as the mean ± SD.*P < 0.05 and **P < 0.01 vs. WKY,
#P < 0.05 and ##P < 0.01 vs. SHR.
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icantly increased. SHR was also signiﬁcantly reduced in LV inﬂow
propagation velocity (Vp) compared with WKY controls (see
Supplemental Data and Fig. 1MeQ).
Invasive hemodynamic evaluation conﬁrmed the echocardio-
graphic ﬁndings. As expected, LV end systolic pressure were
elevated in the SHR and compared with WKY rats. Spontaneously
hypertensive rats had prolonged time constants for isovolumic
relaxation compared with WKY controls (Tau, Glanz: 10.27 ± 1.29
versus 15.05 ± 0.99, P < 0.05; see Supplemental Data and Fig. 1T).
SHR had a steeper end-diastolic pressureevolume relation (EDPVR,
10.27 ± 1.29 versus 15.05 ± 0.99, P < 0.05; see Supplemental Data
and Fig. 1S) compared with WKY rats. LV systolic function was
preserved in SHR compared withWKY rats, as indicated by invasive
indexes, including the peak rate of pressure increase (dP/dtmax)
and slope of the end-systolic pressureevolume relation (ESPVR).
Concentric remodeling of the SHR LV resulted in diastolic
dysfunction, as assessed by invasive hemodynamic and trans-
thoracic echocardiography. Zhong et al. reported that Ang II
induced myocardial hypertrophy diastolic dysfunction and oxida-
tive stress [22]. Silberman et al. also found that diastolic dysfunc-
tion was associated with cardiac oxidation [8]. Consistent with
these results, we observed that the activities of superoxide anion
radical scavenging enzymes SOD and levels of cGMP in the SHR
myocardium were dramatically reduced, whereas the concentra-
tion of MDA was increased compared with WKY rat (Fig. 1UeW).
3.3. Cardiac oxidation was related to less cardiac BH4 and reduced
NO
After four weeks of treatment, we assayed cardiac BH4 content
and its degradation 7,8-dihydrobiopterin (BH2) by HPLC. As shown
in Fig. 2AeC, BH4 levels were remarkably lower in SHR hearts with
diastolic dysfunction (8.70 ± 2.28 versus 29.63 ± 8.86; P < 0.001).
Cardiac BH2 content in SHR was also decreased compared with
WKY rats without diastolic dysfunction (5.06 ± 1.70 versus
8.63 ± 2.20; P ¼ 0.001). The ratio of BH4 to BH2 was signiﬁcantly
lower in SHR compared with WKY control (1.77 ± 0.34 versus
3.45 ± 0.59; P ¼ 0.011).
Tetrahydrobiopterin (BH4) is a crucial cofactor for NO produc-
tion from nitric oxide synthase (NOS). The ratio of reduced BH4 to
oxidized proteins reﬂects the availability of BH4 for NOS. We found
that NO production was reduced in SHR compared with WKY
control (3.09 ± 0.72 versus 4.76 ± 0.79; P < 0.001, Fig. 2D).
Administration BH4 to SHR increased cardiac BH4 (P ¼ 0.026,
SHR versus SHRþ BH4) and the ratio of BH4 to BH2 (P¼ 0.026, SHR
versus SHR þ BH4).
As shown in Fig. 2D, total nitrite/nitrate content, which is
representative NO production of in SHR myocardium, was elevated
after BH4 administration (P ¼ 0.001, SHR versus SHR þ BH4). Thus,
reduced NO production contributed to cardiac oxidation and
resulted in LV diastolic dysfunction in hypertensive rats.
Previous reports and our data indicated that hypertension
caused increased oxidative stress in the LV myocardium. Further,
diastolic dysfunction was associated with cardiac oxidation. These
data (Fig. 2) suggested that BH4 depletion limited NO production in
SHR with diastolic dysfunction.
3.4. BH4 reversed hypertrophic remodeling and comparisons with
valsartan
As previously described, spontaneously hypertensive rats
exhibited concentric hypertrophic remodeling. Two-dimensional
echocardiographic (Fig. 3A) and M-mode images (Fig. 3B)
revealed that hypertrophic LV wall thickness in SHRwas attenuatedby treatment with both BH4 and valsartan. The anti-hypertrophic
remodeling effect of valsartan was stronger than BH4
(Supplemental Data).
The expression of hypertrophy genes a-SA (a-skeletal actin;
Fig. 3E) and b-MHC (b-myosin heavy chain; Fig. 3F) was signiﬁ-
cantly increased in hypertensive rats and decreased after treatment
with BH4 and valsartan. The changes of a-SA and b-MHC mRNA
expression were similar with morphometric results assessed by
echocardiography. The twelve-week-old spontaneously hyperten-
sive rats exhibited a mild degree of myocardial ﬁbrosis. mRNA
expression of TGF-b1 (transforming growth factor-b1), a ﬁbrosis-
associated gene, was increased in SHR and inhibited by BH4
(P¼ 0.006, SHR versus SHR þ BH4; Fig. 3G). Valsartan had no effect
on myocardial TGF-b1expression (P ¼ 0.154, SHR versus
SHRþVAL). These results demonstrated that BH4 and valsartan can
suppress pathological hypertrophy and that BH4 can inhibit
myocardial ﬁbrosis.
The protein expression of Bax and Bcl-2 in the myocardium of
WKY rats and SHR is shown in Fig. 3C and D. Compared with WKY
rats, immunohistochemical analysis indicated that Bax expression
was signiﬁcantly increased and Bcl-2 expression was decreased in
SHR myocardium. However, after BH4 administration, Bax and Bcl-
2 expression was down-regulated and up-regulated, respectively
(P < 0.01), in the WKY group compared with the SHR group. Bax
and Bcl-2 expression in SHR þ VAL rat myocardium was not
signiﬁcantly changed compared with the SHR group. These results
suggested that the mechanisms by which BH4 and valsartan
reversed hypertrophic remodeling were different.
3.5. BH4 restored LV diastolic function and up-regulated
phosphorylated Akt levels
We assessed the expression of PI3K, Akt and phosphorylated Akt
levels in cardiac tissues using Western blotting. PI3K expression
was signiﬁcantly decreased in SHR compared with WKY rats
(Fig. 4G and I). Akt expression was not different between SHR and
WKY rats, whereas BH4 and valsartan administration had no effect
on this protein. Compared with control WKY rats, the amount of
cardiac phosphorylated Akt for serine 473 and threonine 308 was
decreased in SHR with diastolic dysfunction (Fig. 4G, H). We
assessed whether BH4 and valsartan affected phosphorylated Akt
levels. BH4 increased the serine and threonine Akt phosphoryla-
tion, whereas valsartan decreased serine and threonine Akt phos-
phorylation (Fig. 4). Phosphoinositide 3-kinase (PI3K) and its
downstream effector Akt are involved in regulating cardiac cell
proliferation, survival, and apoptosis. Phosphorylated Akt has been
reported to preserve cardiac function [17].
In this present study, the invasive hemodynamic assessment
(Fig. 4DeF) and echocardiographic measurement (Fig. 4AeC)
conﬁrmed that both BH4 and valsartan can restore the LV diastolic
function in SHR. SHR with diastolic dysfunction were characterized
by reduced E0/A0 ratio, augmented E/E0 ratio, lower Vp velocity,
elevated LV end-diastolic pressure, increased end-diastolic pres-
sure volume slope, and increased LV relaxation time constant,
which were all rescued by treatment with BH4 and valsartan
(Fig. 4AeF). However, our results demonstrated that only BH4 can
up-regulate phosphorylated Akt levels in serine 473 and threonine
308 (Fig. 4H, J and K). These results showed that exogenous BH4 can
improve diastolic dysfunction in SHR, partly by promoting the PI3K/
phosphorylated Akt signaling pathway.
4. Discussion
Diastolic dysfunction associated with hypertension leads to
cardiac hypertrophic remodeling. Our study demonstrated that
P. Chang et al. / Biochemical and Biophysical Research Communications 463 (2015) 1012e1020 1019exogenous chronic BH4 and valsartan treatment for one month can
sustain blood pressure reduction and reverse concentric hyper-
trophic remodeling in SHR. Compared with valsartan administra-
tion, the reduction of blood pressure and cardiac hypertrophy for
BH4was comparativelymodest and did not induce changes in heart
rate. Exogenous BH4 has been reported to ameliorate pre-existing
advanced left ventricular hypertrophy/ﬁbrosis and was more
effective than tempol, a less targeted anti-oxidant [23].
Many studies have highlighted the important role of myocyte
NOS uncoupling in cardiac hypertrophic remodeling and diastolic
dysfunction [8,23e26]. This morphometric and functional defect
was associated with reduced NOS NO production and cardiac
oxidation. Our results were consistent with those of Moens and
Takimoto et al. [23]. BH4 reversed chronic hypertrophic remodeling
and diastolic dysfunction. In contrast, cGMP, SOD and NO produc-
tionwere increased in the SHRþ BH4 group comparedwith control
SHR. Thus, chronic supplementation of exogenous BH4 can alle-
viate oxidative stress in SHR hearts.
Cardiac hypertrophy has been reported to develop by 4 weeks of
age in SHR, and diastolic dysfunction is evident at 2e3months [27].
The present ﬁndings demonstrated that chronic persistent high
blood pressure induced morphological, functional and molecular
alterations in SHR hearts, leading to cardiac hypertrophy with
decreased myocardial compliance and inhibited diastolic function.
Both BH4 and valsartan decreased mRNA expression of a-SA and b-
MHC, lowered blood pressure and improved diastolic function. We
also found that BH4 can inhibit the expression of l TGF-b1 and
myocardial ﬁbrosis. Angiotensin receptor blockers can blunt cardiac
hypertrophy and diastolic dysfunction progression [28], but BH4
reversed these heart abnormalities supported by detrimental
anoxygenic properties.
In this present study, LV diastolic dysfunction was accompanied
by impaired activation of the PI3K/p-Akt signaling pathway. Akt is
an important regulator of the downstream effects of PI3K, which
mediates cell proliferation and survival. Recent studies have shown
that PI3K/Akt signaling pathway activation prevented car-
diomyocyte apoptosis and protected the myocardium from
ischemic injury.
Previous studies have shown that in the adult heart, short-term
Akt activation can induce cardiac hypertrophy and does not affect
contractile function, which can enhance myocardial vascular
endothelial growth factor secretion and promote coronary angio-
genesis [29]. Akt increases the expression of sarcoplasmic reticu-
lum calcium ATPase 2 (SERCA2) and improves cardiac function in
mice [30,31]. Akt can promote cell survival and improve cardiac
function through phosphorylation of multiple downstream targets
due to its pro-survival effects [32e34].
The present study showed that the protective effects of BH4
were associated with the PI3K/p-Akt pathway. Exogenous BH4 can
activate phosphorylated Akt expression for serine 473 and threo-
nine 308 in SHR with cardiac hypertrophy and diastolic dysfunc-
tion. BH4 regulated the Bcl-2 family and reduced cardiomyocyte
apoptosis by activation of phosphorylated Akt, whereas valsartan
can reverse cardiac hypertrophy and improve diastolic function
without affecting phosphorylated Akt expression. The PI3K/Akt
signaling pathway regulates growth and survival; activating Akt
phosphorylation plays a crucial role in this pathway, and inhibition
of the phosphorylation of Akt results in apoptosis [35e37].
Our study has several limitations. Although we found that BH4
prevents the progression of hypertrophic remodeling and cardiac
function, this action is not necessarily the primary mechanism.
In summary, less BH4 and reduced NO increases myocardial
hypertrophy and cardiac oxidative stress, which exacerbates dia-
stolic dysfunction. This cardiac dysfunction and pathological
remodeling can be reversed to some degree by BH4 treatment. BH4may be a potent therapy for hypertension with diastolic
dysfunction.
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